Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

C. Ethan Byrne; Carlos E. Astete; Manibarathi Vaithiyanathan; Adam T. Melvin; Mahsa Moradipour; Stephen E. Rankin; Barbara L. Knutson; Cristina M. Sabliov; Elizabeth C. Martin

doi:10.2217/nnm-2020-0010

Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

C. Ethan Byrne, Carlos E. Astete, Manibarathi Vaithiyanathan, Adam T. Melvin, Mahsa Moradipour, Stephen E. Rankin, Barbara L. Knutson, Cristina M. Sabliov, Elizabeth C. Martin

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro.

Original language	English
Pages (from-to)	981-1000
Number of pages	20
Journal	Nanomedicine
Volume	15
Issue number	10
DOIs	https://doi.org/10.2217/nnm-2020-0010
State	Published - Apr 2020

Bibliographical note

Publisher Copyright:
© 2020 © 2020 Future Medicine Ltd.

Keywords

breast cancer
drug delivery
lignin
nanoparticle
targeted therapies
triple-negative

ASJC Scopus subject areas

Bioengineering
Medicine (miscellaneous)
Biomedical Engineering
General Materials Science
Development

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/nnm-2020-0010

Cite this

@article{5eeb466595d14183a5bd9fd73c6a23d2,

title = "Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line",

abstract = "Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro.",

keywords = "breast cancer, drug delivery, lignin, nanoparticle, targeted therapies, triple-negative",

author = "Byrne, {C. Ethan} and Astete, {Carlos E.} and Manibarathi Vaithiyanathan and Melvin, {Adam T.} and Mahsa Moradipour and Rankin, {Stephen E.} and Knutson, {Barbara L.} and Sabliov, {Cristina M.} and Martin, {Elizabeth C.}",

note = "Publisher Copyright: {\textcopyright} 2020 {\textcopyright} 2020 Future Medicine Ltd.",

year = "2020",

month = apr,

doi = "10.2217/nnm-2020-0010",

language = "English",

volume = "15",

pages = "981--1000",

number = "10",

}

TY - JOUR

T1 - Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

AU - Byrne, C. Ethan

AU - Astete, Carlos E.

AU - Vaithiyanathan, Manibarathi

AU - Melvin, Adam T.

AU - Moradipour, Mahsa

AU - Rankin, Stephen E.

AU - Knutson, Barbara L.

AU - Sabliov, Cristina M.

AU - Martin, Elizabeth C.

PY - 2020/4

Y1 - 2020/4

N2 - Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro.

AB - Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic-co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro.

KW - breast cancer

KW - drug delivery

KW - lignin

KW - nanoparticle

KW - targeted therapies

KW - triple-negative

UR - http://www.scopus.com/inward/record.url?scp=85084316685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084316685&partnerID=8YFLogxK

U2 - 10.2217/nnm-2020-0010

DO - 10.2217/nnm-2020-0010

M3 - Article

C2 - 32238059

AN - SCOPUS:85084316685

SN - 1743-5889

VL - 15

SP - 981

EP - 1000

JO - Nanomedicine

JF - Nanomedicine

IS - 10

ER -

Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this